In direct compression tablet manufacturing for oral administration, the particle size distribution and flow properties of (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide determine whether a rotary tablet press can maintain weight variation below the compendial threshold. The pharma-grade API is milled on a fluidized-bed jet mill to a laser diffraction d₉₀ of 45 µm to 150 µm and a d₁₀ no lower than 5 µm, because a finer fraction increases surface area but reduces powder flow. If the API is stored or handled at relative humidity above 60%, pre-drying in a vacuum dryer at 40°C to 50°C for 4 h to 6 h is required before blending, because surface moisture increases punch sticking and weight variance. A container blender with 600 L working volume and 70% fill ratio is operated at 6 RPM to 12 RPM for 20 min to 30 min in the pre-lubrication phase; the API mass fraction in the tablet core is held between 8.0 wt% and 25.0 wt% for dose strengths of 10 mg to 50 mg in a 200 mg core. Lubrication uses magnesium stearate at 0.5 wt% to 1.0 wt% with a final blend time of 3 min to 5 min to avoid overlubrication, which lowers tablet hardness and delays dissolution. Compression is performed on a Korsch XL 400 or Fette 1200i rotary tablet press with 47 stations, precompression force 5 kN to 12 kN, main compression force 30 kN to 80 kN, and turret speed 40 RPM to 80 RPM. The production-scale failure mode observed on similar small-molecule crystalline APIs is punch face filming when tablet press run time exceeds 4 h without forced feeder cleaning or when the glidant fraction is below 0.2 wt%. In-process control tests require tablet weight 200 mg ± 3%, hardness 50 N to 120 N, friability ≤ 1.0%, and disintegration ≤ 15 min in 0.1 M hydrochloric acid at 37°C. The applicable compliance standards are USP <905> uniformity of dosage units, USP <711> dissolution, USP <1216> powder flow characterization, ICH Q7, and 21 CFR 211.165. The terminal product type is an immediate-release film-coated tablet for oral administration. Because published production-scale data specific to this exact chiral API is limited, the stated ranges represent a development starting point and require confirmation on full-scale batches.

When Does Capsule Fill Weight Variability Exceed USP <905> Uniformity Limits?

Capsule fill weight variability in hard gelatin or hypromellose capsule filling is driven by powder bed density fluctuations inside the hopper, tamping pin force, and API cohesion. For (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide in a low-dose oral capsule formulation, the API mass fraction is maintained at 10.0 wt% to 30.0 wt% of a 250 mg to 350 mg fill weight. The diluent system is spray-dried lactose with microcrystalline cellulose, croscarmellose sodium at 2.0 wt% to 4.0 wt%, and sodium stearyl fumarate at 0.5 wt% to 1.0 wt%. Filling is executed on a Bosch GKF 2000 or Zanasi 40E capsule filler with 0.4 mm to 0.8 mm tamping pin gap and 20 mm to 30 mm powder column height. The capsule weight relative standard deviation is monitored at ≤ 2.0%; an increase above 3.0% triggers hopper level adjustment and tribostatic grounding of contact surfaces. The applicable compliance standards are USP <905>, USP <701> disintegration, USP <711> dissolution, ICH Q8, and 21 CFR 211.165. Capsule shell selection follows ICH Q3D elemental impurity limits and USP <711> dissolution media compatibility. The terminal product types are single-phase powder-filled capsules or granule-filled capsules for oral administration; band-sealing is applied when moisture protection is required.

High-Shear Wet Granulation Torque Endpoint and Binder Dispersion Control

Wet granulation of (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide is used only when direct compression fails due to segregation or when the API exhibits poor compaction under high tablet compression force. The dry granulation charge contains 20.0 wt% to 40.0 wt% API and uses a hypromellose binder solution at 2.0% w/w to 6.0% w/w in purified water added at 0.5 kg/min to 1.5 kg/min into a GEA PharmaConnect 300 or Collette UltimaGral 150 high-shear mixer. Impeller speed is ramped from 200 RPM to 500 RPM, while chopper speed is fixed between 1500 RPM and 3000 RPM. The granulation endpoint is determined by impeller torque increase of 20% to 40% above the dry-mix baseline, corresponding to wet mass density of 0.55 g/cm³ to 0.75 g/cm³. Wet milling through a 1.0 mm to 3.0 mm screen followed by fluid-bed drying at inlet air temperature 55°C to 70°C to final loss on drying of 1.0% to 2.5% prevents granule collapse and excessive residual moisture. Overgranulation is a known failure mode that produces dense granules with a high torque plateau and prolonged disintegration above 15 min. Process compliance relies on ICH Q8 design space verification, ICH Q9, USP <701>, USP <905>, USP <711>, and 21 CFR 211.165. The terminal product types are film-coated tablets or capsule-filled granules, including modified-release forms when the granulated API is coated with a release-controlling polymer.

If Terminal Sterilization Destabilizes the Aqueous Injectable, Aseptic Filtration Becomes the Critical Control Point

If thermal degradation kinetics for (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide at 121°C for 15 min produce total impurities approaching 1.0%, terminal sterilization is rejected in favor of aseptic filtration. Aseptic solution manufacturing uses a 316L stainless-steel jacketed mixing vessel with nitrogen overlay, water for injection at 20°C to 30°C, and pH adjustment to 4.5 to 6.5 with dilute hydrochloric acid or sodium hydroxide. The formulation addition ratio corresponds to an API concentration of 5.0 mg/mL to 20.0 mg/mL, with tonicity adjusted to 270 mOsm/kg to 320 mOsm/kg using sodium chloride or mannitol. The solution is prefiltered through 0.45 µm polyethersulfone and sterile-filtered through 0.22 µm PVDF or PES membrane cartridges under 1.0 bar to 3.0 bar differential pressure. Filling is performed on a Bausch+Strobel AFG 5000 or Syntegon FLC 3085 line in a Grade A isolator with fill volume control of ± 2.5%, 100% in-line checkweighing, and a reject rate target below 0.25%. Filter fouling is an observed failure mode when the API precipitates during pH adjustment or when the solution is held above 8 h before filtration. The applicable compliance framework is EU GMP Annex 1, 21 CFR 210/211, USP <1>, USP <85>, USP <788>, USP <790>, and ICH Q10. The terminal product types are single-dose or multi-dose vials for intravenous, intramuscular, or subcutaneous administration, supplied as ready-to-inject solution.

Managing Lyophilization Cake Collapse in Amorphous API Formulations

Freeze-drying is applied when the API's aqueous solubility limits the solution concentration or when hydrolytic degradation during liquid storage requires a dry injectable format. The lyophilized formulation contains (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide at 1.0 wt% to 4.0 wt% in water for injection, with mannitol at 2.0% w/v to 5.0% w/v or trehalose at 2.0% w/v to 10.0% w/v to provide cake mechanical strength. The solution is filled into 10R or 20R type I glass vials at 2.5 mL to 10.0 mL. The lyophilization cycle uses shelf freezing at -45°C for 2 h to 4 h, primary drying at shelf temperature -20°C to -10°C and chamber pressure 66.7 Pa to 200 Pa, and secondary drying at 20°C to 40°C for 6 h to 12 h. Product temperature probes and comparative pressure measurement are used to ensure the product temperature remains below the collapse temperature during primary drying; cake cracking is observed when primary drying pressure is raised too quickly from the annealing step. The applicable standards are USP <1>, USP <788>, USP <921> water determination, USP <790>, 21 CFR 211.165, and ICH Q8. The terminal products are lyophilized powder or cake in vials for reconstitution, with the reconstituted solution intended for injection or infusion after dilution.

Under aseptic filling conditions for a prefilled syringe or cartridge, the primary packaging interaction with the (S)-N-(2,6-dimethylphenyl)piperidine-2-carboxamide solution is evaluated using ISO 7886-1:2017 and ISO 11040-4:2015. The solution API concentration is restricted to 1.0 mg/mL to 10.0 mg/mL, with pH 4.5 to 6.5 and dynamic viscosity below 10 mPa·s at 25°C to ensure smooth injection through a 27G needle. The glass barrel is siliconized with baked-on silicone; tungsten leachables from the needle tip forming process are controlled by positional monitoring and by the supplier's tungsten oxidation state. Filling is performed on a modular aseptic filling line with 0.22 µm sterile filtration, inert gas overlayment in the headspace, and plunger insertion under vacuum. Process failure modes include silicone oil droplet migration above 5 µm and subvisible particle formation after accelerated storage at 40°C and 75% relative humidity. Compliance is anchored to USP <1>, USP <788>, USP <790>, 21 CFR 211.165, EU GMP Annex 1, and ICH Q3D. The terminal product types are single-dose prefilled syringes or cartridges for manual injection or for use in a pen injector.

Because dry syrup and sprinkle oral formulations require the API to remain stable through high-humidity storage conditions, an oral granule process is selected when tablet and capsule formats are unsuitable for paediatric or elderly administration. The API is incorporated at 1.0 wt% to 5.0 wt% of a 500 mg to 1.0 g sachet fill, with the balance consisting of compressible sugar, microcrystalline cellulose, and a polyvinylpyrrolidone binder solution at 2.0% w/w to 5.0% w/w. Granulation is performed in a top-spray fluid-bed processor with inlet air temperature 45°C to 65°C, product temperature 28°C to 38°C, spray rate 5 g/min to 15 g/min, and final loss on drying 1.5% to 2.5%. The dried granules are sieved to 150 µm to 850 µm before dose filling; electrostatic adhesion to sachet film is a known filling-line failure mode when the granule moisture content falls below 1.0%. The applicable compliance standards are USP <711>, USP <905>, USP <701>, ICH Q7, and 21 CFR 211.165. The terminal product types are single-dose sachets for oral suspension or direct sprinkle administration.